Literature DB >> 25644670

Low frequency magnetic field therapy in patients with cytostatic-induced polyneuropathy: a phase II pilot study.

Georg Geiger1, Eberhard Mikus, Hermann Dertinger, Oliver Rick.   

Abstract

Cytostatic-induced polyneuropathy (CIPN) is a common and serious toxicity in tumor patients. Treatment and prophylactic measures are mainly ineffective. Therefore, there is an urgent need to establish a sufficient therapy for pPNP. Between July 2007 and August 2008, 20 patients were treated with low frequency (4-12 Hz) magnetic field therapy (MFT), and neurological examinations were conducted at the trial therapy's beginning, as well as after 3-4 weeks. Standardized testing methods were applied, i.e., the Common Toxicity Criteria questionnaire of the National Cancer Institute and the measurement of nerve conduction velocity (NCV) in the electrophysiological examination. In terms of the components sensory ataxia and neuropathy as well as neuropathic pain, an improvement was achieved using MFT. This effect was confirmed by an increase in NCV. Using low frequency MFT, CIPN was influenced positively on both hands and feet. This could represent a future therapy principle for these patients.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemotherapy; toxicity; tumor patients

Mesh:

Substances:

Year:  2015        PMID: 25644670     DOI: 10.1002/bem.21897

Source DB:  PubMed          Journal:  Bioelectromagnetics        ISSN: 0197-8462            Impact factor:   2.010


  2 in total

Review 1.  Pharmacological and Nonpharmacological Management of Chemotherapy-Induced Peripheral Neuropathy: A Scoping Review of Randomized Controlled Trials.

Authors:  Katie Fitzgerald Jones; Stephen Wechsler; David Zulewski; Lisa Wood
Journal:  J Palliat Med       Date:  2022-02-04       Impact factor: 2.947

2.  Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study.

Authors:  Oliver Rick; Ulrike von Hehn; Eberhard Mikus; Hermann Dertinger; Georg Geiger
Journal:  Bioelectromagnetics       Date:  2016-09-22       Impact factor: 2.010

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.